HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 214 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,115 | +237.9% | 29,191 | +219.0% | 0.11% | +164.3% |
| Q2 2023 | $330 | -61.7% | 9,152 | -59.4% | 0.04% | -46.8% |
| Q1 2023 | $861 | -99.9% | 22,543 | +7.7% | 0.08% | -24.0% |
| Q2 2022 | $921,000 | +205.0% | 20,930 | +22.9% | 0.10% | +116.7% |
| Q4 2019 | $302,000 | +48.0% | 17,036 | +43.5% | 0.05% | +41.2% |
| Q2 2019 | $204,000 | +3.6% | 11,871 | +9.9% | 0.03% | +25.9% |
| Q3 2018 | $197,000 | -17.9% | 10,806 | -24.1% | 0.03% | -25.0% |
| Q2 2018 | $240,000 | -76.0% | 14,235 | -72.1% | 0.04% | -75.8% |
| Q1 2018 | $1,000,000 | +440.5% | 51,050 | +380.0% | 0.15% | +396.7% |
| Q3 2017 | $185,000 | +8.2% | 10,636 | -20.2% | 0.03% | -6.2% |
| Q2 2017 | $171,000 | -11.4% | 13,336 | -31.9% | 0.03% | -38.5% |
| Q4 2016 | $193,000 | +43.0% | 19,589 | +75.0% | 0.05% | +44.4% |
| Q3 2016 | $135,000 | -4.3% | 11,193 | +5.7% | 0.04% | -25.0% |
| Q3 2015 | $141,000 | – | 10,594 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SNYDER CAPITAL MANAGEMENT L P | 4,324,232 | $165,185,662 | 3.73% |
| Steamboat Capital Partners, LLC | 196,898 | $7,521,504 | 2.79% |
| 2Xideas AG | 600,799 | $22,950,522 | 2.54% |
| BERNZOTT CAPITAL ADVISORS | 171,808 | $6,563,066 | 2.26% |
| Redwood Investments, LLC | 328,459 | $12,547,134 | 1.70% |
| Mesirow Institutional Investment Management, Inc. | 380,415 | $14,531,853 | 1.47% |
| Granite Investment Partners, LLC | 856,253 | $32,708,865 | 1.37% |
| Penn Capital Management Company, LLC | 324,707 | $12,453,211 | 1.28% |
| EFG Asset Management (North America) Corp. | 137,739 | $5,262,319 | 1.25% |
| First Light Asset Management, LLC | 313,536 | $11,977,075 | 1.14% |